US20230372315A1 - Liquid-State Pharmaceutical Composition Exhibiting Excellent Preservative Effectiveness - Google Patents
Liquid-State Pharmaceutical Composition Exhibiting Excellent Preservative Effectiveness Download PDFInfo
- Publication number
- US20230372315A1 US20230372315A1 US18/246,775 US202118246775A US2023372315A1 US 20230372315 A1 US20230372315 A1 US 20230372315A1 US 202118246775 A US202118246775 A US 202118246775A US 2023372315 A1 US2023372315 A1 US 2023372315A1
- Authority
- US
- United States
- Prior art keywords
- composition
- present
- salt
- compound
- benzyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003755 preservative agent Substances 0.000 title claims abstract description 30
- 230000002335 preservative effect Effects 0.000 title claims abstract description 30
- 230000001747 exhibiting effect Effects 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 208
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract description 156
- 150000003839 salts Chemical class 0.000 claims abstract description 65
- 239000007788 liquid Substances 0.000 claims abstract description 60
- 235000019445 benzyl alcohol Nutrition 0.000 claims abstract description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 49
- 150000001875 compounds Chemical class 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 36
- 150000001720 carbohydrates Chemical class 0.000 claims description 30
- 239000003002 pH adjusting agent Substances 0.000 claims description 27
- 239000000872 buffer Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 150000005846 sugar alcohols Chemical class 0.000 claims description 6
- 150000002016 disaccharides Chemical class 0.000 claims description 5
- 150000002772 monosaccharides Chemical class 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- TUWCZRFHNIOVTC-UHFFFAOYSA-N fuzapladib Chemical compound CCS(=O)(=O)NC1=NC=C(C(F)(F)F)C=C1NC(=O)C1CCCCC1 TUWCZRFHNIOVTC-UHFFFAOYSA-N 0.000 abstract description 18
- 230000000844 anti-bacterial effect Effects 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 241000588724 Escherichia coli Species 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 16
- 238000011081 inoculation Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 229940125904 compound 1 Drugs 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 235000010355 mannitol Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- 229960000281 trometamol Drugs 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 241000233866 Fungi Species 0.000 description 8
- 206010033645 Pancreatitis Diseases 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 8
- 241001331781 Aspergillus brasiliensis Species 0.000 description 7
- 241000222122 Candida albicans Species 0.000 description 7
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000009545 invasion Effects 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001139 pH measurement Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- -1 alkali metal salts Chemical class 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- QIGJYVCQYDKYDW-NSYYTRPSSA-N nigerose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-NSYYTRPSSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ABXYOVCSAGTJAC-JGWLITMVSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanethial Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S ABXYOVCSAGTJAC-JGWLITMVSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 206010052541 Gastric volvulus Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000018650 Intervertebral disc disease Diseases 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- OKPQBUWBBBNTOV-UHFFFAOYSA-N Kojibiose Natural products COC1OC(O)C(OC2OC(OC)C(O)C(O)C2O)C(O)C1O OKPQBUWBBBNTOV-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 239000006391 Luria-Bertani Medium Substances 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 101800001776 Nuclear inclusion protein B Proteins 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037651 Pyometra Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- HIWPGCMGAMJNRG-ACCAVRKYSA-N Sophorose Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HIWPGCMGAMJNRG-ACCAVRKYSA-N 0.000 description 1
- 208000008886 Stomach Volvulus Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- HIWPGCMGAMJNRG-UHFFFAOYSA-N beta-sophorose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)C(CO)O1 HIWPGCMGAMJNRG-UHFFFAOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940121564 fuzapladib Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- PZDOWFGHCNHPQD-OQPGPFOOSA-N kojibiose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-OQPGPFOOSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- QIGJYVCQYDKYDW-LCOYTZNXSA-N laminarabiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-LCOYTZNXSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 201000002765 pyometritis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- QBUPAAMUKRHOPD-UHFFFAOYSA-M sodium [3-(cyclohexanecarbonylamino)-5-(trifluoromethyl)pyridin-2-yl]-ethylsulfonylazanide hydrate Chemical compound O.[Na+].CCS(=O)(=O)Nc1ncc(cc1[N-]C(=O)C1CCCCC1)C(F)(F)F QBUPAAMUKRHOPD-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PZDOWFGHCNHPQD-VNNZMYODSA-N sophorose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-VNNZMYODSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Definitions
- the present invention relates to a liquid composition containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide exhibiting excellent preservative effectiveness or a salt thereof.
- N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof is known to have phospholipase A2 inhibitory action and be useful as an active ingredient of an anti-inflammatory agent or an anti-pancreatitis agent (Patent Document 1).
- Therapeutic agents or prophylactic agents for digestive disorders, liver diseases, pulmonary insufficiency or shock lung, containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof as an active ingredient, are also known (Patent Documents 2, 3, 4 and 5).
- Patent Documents 1 to 5 disclose compositions for preparations such as an injection, containing the active ingredient mentioned above and also disclose that such compositions may contain an antibacterial agent such as benzyl alcohol.
- Benzyl alcohol is an antibacterial agent widely used in injections and optimal antibacterial activity thereof is exhibited at less than pH5 and virtually no antibacterial activity is exhibited beyond pH8 (non-Patent Document 1).
- Non-Patent Document 1 N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof is virtually not dissolved in water having pH5 or less.
- N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof in the form of a composition such as an injection, in particular, a composition filled in a multiple-use vial, for a long period of time. Accordingly, it has been desired to develop technical means for enhancing preservative effectiveness of a liquid composition containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof.
- Patent Document 1 Japanese Patent Laid-Open No. H06-263735
- Patent Document 2 International Publication No. WO2001/056568
- Patent Document 3 International Publication No. WO2001/056569
- Patent Document 4 International Publication No. WO2001/056570
- Patent Document 5 International Publication No. WO2010/137484
- Non-Patent Document 1 Handbook of Pharmaceutical Excipients, eighth edition (2017), p.105
- N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide (Fuzapladib) is a compound represented by the structural formula of the following formula (1) and hereinafter will be sometimes simply referred to as the compound of formula (1).
- an object of the present invention is to provide a liquid composition containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof and having an enhanced preservative effectiveness.
- the composition of the present invention is advantageous since it is used as a composition for multiple administration, for example, a composition filled in a multiple-use vial.
- the liquid composition of the present invention is characterized by containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof and water together with benzyl alcohol, and having pH of 8 or more.
- N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide of the present invention is represented by the structural formula (1).
- a salt of the compound of the formula (1) may be any salt can be used as long as it is a pharmaceutically acceptable salt.
- the salt include alkali metal salts such as a potassium salt and a sodium salt; alkaline earth metal salts such as a calcium salt; and organic amine salts such as a triethanolamine salt and a tris (hydroxymethyl)aminomethane salt.
- a salt of the compound of formula (1) may be any one of these salts having crystal water, more specifically, a hydrate thereof.
- the compound of formula (1) or a salt thereof can be produced, for example, by a method disclosed in Japanese Patent Laid-Open No. H06-263735.
- the content of the compound of formula (1) or a salt thereof in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention.
- the content thereof can be, for example, 0.001 to 15 w/v (mass/volume) % based on the composition, preferably 0.005 to 10 w/v %, more preferably 0.01 to 5 w/v %, further preferably 0.01 to 1 w/v %, and further preferably 0.1 to 1 w/v %.
- the content of the compound of formula (1) or a salt thereof in the composition of the present invention can be measured by HPLC method, for example, in accordance with the method disclosed in Example 1 of International Publication No. WO2019/167979.
- benzyl alcohol can be used for providing preservative effectiveness.
- the content of benzyl alcohol in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention.
- the lower limit of the content of benzyl alcohol is, for example, 0.8 w/v % or more, preferably 0.9 w/v % or more, and more preferably 1.2 w/v % or more.
- the upper limit of the content of benzyl alcohol is, for example, 5 w/v % or less, preferably 4 w/v % or less, more preferably 3 w/v % or less, and further preferably 2 w/v % or less.
- the content is, for example, 0.9 to 5 w/v % based on the composition, preferably 0.9 to 4 w/v %, more preferably 0.9 to 3 w/v %, and further preferably 1.2 to 2 w/v %.
- the content of benzyl alcohol in the composition of the present invention can be measured, for example, by HPLC (method) but other methods routinely used in the technical field can be used for measurement.
- the mass ratio of the compound of formula (1) or a salt thereof to benzyl alcohol [mass ratio of the compound of formula (1) or a salt thereof:benzyl alcohol] can be, for example, 1:1.9 to 1:20, preferably 1:2.1 to 1:20, more preferably 1:2.2 to 1:10, and further preferably 1:3 to 1:5.
- Water to be used in the present invention is not particularly limited, for example, water that is used as a pharmaceutical or food and will be used in the future are included.
- water include purified water, ion-exchanged water, distilled water, hyperfiltration water, ultrapure water (for example, milli-Q water), water for injection and saline.
- water for injection is used.
- the composition may further contain a saccharide.
- a saccharide examples include, but are not particularly limited to, saccharides that are used as a pharmaceutical and food and will be used in the future.
- the saccharide of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention.
- the saccharide include a monosaccharide, a disaccharide, a polysaccharide, a sugar alcohol, and a combination of these.
- a monosaccharide, a disaccharide or a sugar alcohol, and more preferably a sugar alcohol is used.
- Examples of the monosaccharide include glucose, galactose, mannose, fructose, psicose, allose, sorbose, arabinose, galactosamine, glucosamine, xylose, thioglucose, deoxyribose, fucose, and a combination of these.
- glucose is used.
- disaccharide examples include lactose, sucrose, maltose, isomaltose, nigerose, kojibiose, trehalose, gentiobiose, cellobiose, sophorose, nigerose, palatinose, melibiose, laminaribiose, and a combination of these.
- lactose is used.
- polysaccharide examples include dextrin, glycogen, starch, processed starch, and a combination of these. Preferably dextrin or starch is used.
- sugar alcohol examples include mannitol, sorbitol, inositol, xylitol, magnesium gluconate, maltitol, meglumine, and a combination of these.
- mannitol and more preferably D-mannitol is used.
- a water-soluble saccharide is preferable as the saccharide of the present invention.
- the term “water solubility” of a saccharide that can be used in the present invention refers to a property belonging to “extremely soluble”, “easy to dissolve”, “slightly easy to dissolve” or “slightly difficult to dissolve”, which is defined in the general rule of the 17th revised Japanese Pharmacopoeia.
- the solubility of a saccharide of the present invention to, for example, water is about 10 mg/mL or more at normal temperature for handling, for example, room temperature of about 20° C., preferably about 33 mg/mL or more, and more preferably 100 mg/mL or more.
- the content of a saccharide in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention but the content is, for example, 0.01 to 20 w/v % based on the composition, preferably 0.1 to 10 w/v %, and more preferably 1 to 3 w/v %.
- the composition may further contain a pH adjuster.
- the pH adjuster is not particularly limited. Examples of the pH adjuster includes pH adjusters that are used as a pharmaceutical or food and will be used in the future.
- the pH adjuster herein, a compound suitable for adjusting pH of a liquid composition to be 8 or more, for example, a value later described (for example, pH8 to 11) is used.
- the pH adjuster may contain a buffer.
- the buffer herein may be a buffer substance or buffer solution which adjusts pH, which has been changed with an acid or a base, to be a desired pH. Accordingly, the pH adjuster to be contained in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention.
- Examples of the pH adjuster include an acid, a base and a buffer.
- Examples of the acid include organic acids or inorganic acids.
- Specific acid include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, maleic acid, acetic acid, citric acid, tartaric acid, propionic acid, succinic acid, oxalic acid, lactic acid, malic acid, glutamic acid, pamoic acid, and a combination of these.
- hydrochloric acid, phosphoric acid, acetic acid or citric acid may be used.
- Examples of the base include organic bases or inorganic bases.
- Specific base include sodium hydroxide, potassium hydroxide, ammonia, tromethamine (tris), and a combination of these.
- sodium hydroxide or tromethamine (tris) may be used.
- the buffer is not particularly limited as long as it does not interfere with the effect of the present invention.
- the buffer include organic acid salts such as an acetate, a lactate, a tartrate, a citrate, a succinate, histidine hydrochloride and a phosphate (for example, potassium phosphate, sodium phosphate); aqueous buffers commonly known in the field of solution preparations such as a citrate buffer (for example, sodium citrate buffer), a tris buffer (for example, tris-HCl buffer), a histidine buffer, an imidazole buffer, a carbonate buffer, a triethanolamine buffer; and a combination of these.
- organic acid salts such as an acetate, a lactate, a tartrate, a citrate, a succinate, histidine hydrochloride and a phosphate (for example, potassium phosphate, sodium phosphate)
- aqueous buffers commonly known in the field of solution preparations such as a citrate buffer (for example, sodium
- the concentration of an acid or a base in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention.
- the concentration thereof is for example, 0.001 to 2 w/v %, preferably 0.01 to 1.5 w/v %, and more preferably 0.1 to 1 w/v %.
- the concentration of a buffer in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention.
- the concentration thereof is, for example, 1 to 500 mM, preferably 5 to 200 mM, and more preferably 10 to 100 mM.
- the composition of the present invention may contain, optionally, a pharmaceutically acceptable additive.
- a pharmaceutically acceptable additive include, but are not particularly limited to, an aqueous medium, a solvent, a base, a solubilizing agent, a tonicity agent, a stabilizer, an adjuster, a chelating agent, an excipient, a thickener, a coloring agent, an antioxidant, a dispersant, an emulsifier and a solubilizer.
- An additive can be blended within the range in which the effect of the present invention is not impaired.
- the dosage form of the composition of the present invention is a liquid.
- the composition of the present invention contains the compound of formula (1) or a salt thereof, benzyl alcohol and water in combination.
- the dosage form of the composition is not particularly limited as long as it keeps a characteristics of the combination.
- the composition can be provided as a dosage form such as an injection, a drip, a syrup or an enema.
- the dosage form is preferably an injection or a drip.
- Examples of the injection include, products prepared by filling vials or syringes with the composition of the present invention.
- Examples of the vial include a single-use vial or a multiple-use vial. Preferably, a multiple-use vial is used.
- multiple is, for example, 2 to 20 times, and preferably, 3 to 18 times. Note that, if a multiple-use vial is used, it is preferable to maintain preservative effectiveness of the composition of the present invention even after the vial is punctured.
- the composition of the present invention may be a composition for single administration or multiple administration, preferably multiple administration.
- the composition include a composition filled in a vial, preferably a composition filled in a multiple-use vial.
- the term “multiple” is as defined above.
- the pH of the composition of the present invention is 8 or more. From the viewpoint of improving solubility of the compound of formula (1) or a salt thereof, the pH is preferably 8 to 11 and more preferably 8 to 10.
- the timing of measuring pH of the composition of the present invention is not particularly limited and may be during the time of production, storage or use of the composition.
- the pH of the composition can be measured by a commercially available pH meter (for example, LAQUA F-74, manufactured by HORIBA Ltd.).
- the composition of the present invention can be produced by mixing the compound of formula (1) or a salt thereof, water and benzyl alcohol, optionally, another solvent in accordance with a method commonly known in the technical field. Since the composition of the present invention may further contain a saccharide and, optionally, a pH adjuster, the composition of the present invention can be produced by mixing the compound of formula (1) or a salt thereof, water, benzyl alcohol, a saccharide and, optionally, a pH adjuster and/or another solvent in accordance with a method commonly known in the technical field.
- the composition of the present invention is produced by mixing/dissolving the compound of formula (1) or a salt thereof, water and benzyl alcohol and, optionally, another solvent in accordance with a method commonly known in the technical field. More specifically, the composition of the present invention is produced, for example, by a method (A) in which the compound of formula (1) or a salt thereof, benzyl alcohol, a saccharide and a pH adjuster are mixed, and then, water is added; a method (B) in which water, benzyl alcohol, a saccharide and a pH adjuster are mixed, and then, the compound of formula (1) or a salt thereof is added; or a method (C) in which water, benzyl alcohol and the compound of formula (1) or a salt thereof are mixed, and then, a saccharide and a pH adjuster are added.
- the mixture may be subjected to homogenization and sterilization processes as long as the effect of the present invention is not impaired.
- the another solvent to be used for producing the composition of the present invention is not particularly limited and a solvent that is used as a pharmaceutical or food and will be used in the future may be included.
- the another solvent include alcohols (for example, methanol, ethanol, propanol, propylene glycol), organic acids (for example, acetic acid, propionic acid), polyethylene glycol, and a mixed solvent of these.
- the preservative effectiveness complies with at least one of the standards defined in USP (for example, USP43-NF38-S2), European Pharmacopoeia (for example, Ph.Eur.10.4) and Japanese Pharmacopoeia (for example, Japanese Pharmacopoeia 17th edition, Japanese Pharmacopoeia 18th edition).
- USP for example, USP43-NF38-S2
- European Pharmacopoeia for example, Ph.Eur.10.4
- Japanese Pharmacopoeia for example, Japanese Pharmacopoeia 17th edition, Japanese Pharmacopoeia 18th edition.
- the preservative effectiveness against, e.g., bacteria is present if the viable count of bacterial cells decreases from 10 5 to 10 6 per the liquid composition of the present invention (1 ml or 1 g) to, for example, 10 2 to 10 3 or less, after 24 hours, preferably 10 1 to 10 2 or less, and more preferably 10 1 or less. It is determined that the preservative effectiveness against, e.g., fungi is present if the viable count of fungus cells per the liquid composition of the present invention (1 ml or 1 g) decreases from 10 5 to 10 6 to, for example, 10 3 to 10 4 or less after 7 days, preferably 10 2 to 10 3 or less, and more preferably 10 1 or less.
- a test for preservative effectiveness can be carried out in accordance with the preservative effectiveness test specified in USP43-NF38-S2 General Chapter ⁇ 51>or Ph.Eur.10.4 General Chapter 5.1.3, in similar conditions disclosed, for example, in Experimental Examples 1, 3 and 4.
- the subject against which the above preservative effectiveness is shown is not particularly limited, but include, for example, bacteria and/or fungi.
- bacteria include Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus .
- fungi include Candida albicans and Aspergillus brasiliensis.
- the composition of the present invention containing the compound of formula (1) or a salt thereof and benzyl alcohol in combination can be used continuously or discontinuously for a long period of time by enhancing preservative effectiveness thereof.
- the composition of the present invention can be used, for example, one day or more, preferably 7 days or more, more preferably 14 days or more, further preferably 21 days or more, and further preferably 28 days or more.
- the upper limit is not particularly limited but preferably 40 days or less.
- kits for producing the composition of the present invention disclosed above consisting of a first composition containing the compound of formula (1) or a salt thereof and a second composition containing benzyl alcohol and water.
- the first composition contains a saccharide and, optionally, a pH adjuster.
- the first composition may have, optionally, a pharmaceutically acceptable additive.
- the saccharides, pH adjuster and pharmaceutically acceptable additive herein are the same as defined above.
- the first composition is preferably lyophilized.
- the first composition is filled in a vial.
- the vial include, a single-use vial and a multiple-use vial.
- a multiple-use vial is used.
- the “multiple” refers to, for example, 2 to 20 times, and preferably, 3 to 18 times. Note that, if a multiple-use vial is used, preservative effectiveness of the composition of the present invention is preferably maintained even after the vial is punctured.
- the content of benzyl alcohol in the second composition is, for example, 0.9 to 5 w/v % based on the whole second composition or the whole composition of the present invention, preferably 0.9 to 4 w/v %, more preferably 0.9 to 3 w/v %, and further preferably 1.2 to 2 w/v %.
- a method for producing the composition of the present invention including mixing a first composition containing the compound of formula (1) or a salt thereof and a second composition containing benzyl alcohol and water.
- a first composition containing the compound of formula (1) or a salt thereof and a second composition containing benzyl alcohol and water.
- the first composition herein is preferably lyophilized.
- the production method may be a method of reconstituting a first composition containing the compound of formula (1) or a salt thereof with benzyl alcohol and water contained in a second composition.
- a first composition may be produced by a method of mixing/dissolving the compound of formula (1) or a salt thereof and a solvent in accordance with a method commonly known in the technical field.
- the first composition is preferably lyophilized. Since the first composition may contain a saccharide and, optionally, a pH adjuster, the first composition may be produced by mixing/dissolving the compound of formula (1) or a salt thereof, a saccharide, optionally, a pH adjuster and a solvent (for example, water and/or another solvent) in accordance with a method commonly known in the technical field.
- the first composition can be produced by mixing/dissolving the compound of formula (1) or a salt thereof, a saccharide and a pH adjuster in water and/or another solvent in accordance with a method commonly known in the technical field. More specifically, the first composition of the present invention is produced, for example, by a method (A) in which the compound of formula (1) or a salt thereof, a saccharide and a pH adjuster are mixed, and then, water is added, a method (B) in which water, a saccharide and a pH adjuster are mixed, and then, the compound of formula (1) or a salt thereof is added, or a method (C) in which water and the compound of formula (1) or a salt thereof are mixed, and then a saccharide and a pH adjuster are added. Thereafter, if necessary, the solution obtained by any one of the aforementioned methods can be lyophilized. In producing the first composition, the first composition may be subjected to homogenization and sterilization processes as long as the effect of the present invention is not
- Another solvent to be used for production of the first composition is the same as defined as another solvent to be used for producing the composition of the present invention.
- the second composition can be produced by mixing benzyl alcohol and water in accordance with a method commonly known in the technical field.
- the second composition may be subjected to homogenization and sterilization processes as long as the effect of the present invention is not impaired.
- the composition of the present invention or first composition can be widely applied to diseases, disease conditions or symptoms in which inflammatory cells (for example, granulocytes (neutrophil, eosinophil, basophil), lymphocytes (for example, T lymphocytes, NK cells), monocytes, macrophages, plasma cells, mast cells, platelets) are involved.
- inflammatory cells for example, granulocytes (neutrophil, eosinophil, basophil), lymphocytes (for example, T lymphocytes, NK cells), monocytes, macrophages, plasma cells, mast cells, platelets.
- diseases, disease conditions or symptoms include pancreatitis, surgical invasion, disseminated intravascular coagulation (DIC), neoplastic disease, pyometra, heatstroke, immune-mediated hemolytic anemia (IMHA), sepsis, angiosarcoma, gastric volvulus, ischemia reperfusion injury, purpura, liver failure, hepatitis, pneumonia, systemic inflammatory response syndrome (SIRS), external wounds, osteoarthritis, cystitis, intervertebral disc disease, atopic/allergy, dermatitis, immune-mediated disease, otitis, inflammatory bowel disease, chronic pain, colitis, chronic obstructive pulmonary disease (COPD), cholecystitis, cholangitis).
- DIC disseminated intravascular coagulation
- IMHA immune-mediated hemolytic anemia
- sepsis angiosarcoma
- gastric volvulus CAD
- ischemia reperfusion injury purpura
- the composition of the present invention or first composition can provide a therapeutic and preventive effect on, e.g., pancreatitis, surgical invasion and disseminated intravascular coagulation (DIC).
- the composition of the present invention or first composition is provided as a composition for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells are involved, preferably, pancreatitis, surgical invasion or disseminated intravascular coagulation (DIC).
- the composition of the present invention or first composition can be used as a pharmaceutical product or quasi-drug for humans or animals.
- the composition of the present invention or first composition may be appropriately used, if necessary, in combination with another pharmaceutical product or quasi-drug commonly used in this technical field. Note that, when the first composition is applied, it is preferably used together with water and benzyl alcohol.
- the subject to which the composition of the present invention is to be applied is, for example, an animal, preferably, a non-human animal such as a mammal, a bird, a reptile, an amphibian and fish, and more preferably, a mouse, a rat, a rabbit, a dog, a cat, a pig, a cow and a horse.
- the animal may be a farm animal, a pet, a human-reared animal, a wild animal and a racing animal.
- the subject may be a healthy person (healthy animal) or a patient (sick animal).
- composition of the present invention is composition for multiple administration, for example, if the composition of the present invention is filled in a multiple-use vial, the subject to which the composition is administered a plurality of times may be the same individual or different individuals (i.e., a plurality of individuals).
- a method for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells of a subject are involved preferably, pancreatitis, surgical invasion or disseminated intravascular coagulation (DIC), including administering the composition of the present invention to the subject.
- the method for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells of a subject are involved is, if the subject is healthy, defined as a non-therapeutic method excluding a medical practice.
- the method for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells of a subject are involved can be carried out in accordance with the content disclosed in the specification with respect to the composition of the present invention.
- the effective amount of the compound of formula (1) of the present invention or a salt thereof and frequency of administration of the composition of the present invention are not particularly limited and appropriately determined by those skilled in the art depending on the type and purity of the compound of formula (1) or a salt thereof, the dosage form of the composition, the type, nature, sex, age and symptom of the subject.
- the effective amount of the compound of formula (1) or a salt thereof is 0.01 to 1000 mg/body weight (kg) and preferably 0.05 to 500 mg/body weight (kg).
- the frequency of administration per the same individual is, for example, 1 to 5 times per day, preferably 1 to 3 times per day, and more preferably once to twice per day.
- the period for administration per the same individual is, for example, 1 to 7 days, preferably 1 to 5 days, and more preferably 1 to 3 days.
- the compound of formula (1) or a salt thereof, benzyl alcohol and water in combination for producing a liquid composition having pH of 8 or more.
- the above composition is used for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells are involved, preferably, pancreatitis, surgical invasion, or disseminated intravascular coagulation (DIC).
- a liquid composition having pH of 8 or more there is provided use of the compound of formula (1) or a salt thereof and benzyl alcohol in combination for enhancing preservative effectiveness of a liquid composition having pH of 8 or more.
- a liquid composition having pH of 8 or more there is provided use of the above components in combination for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells are involved, preferably, pancreatitis, surgical invasion or disseminated intravascular coagulation (DIC).
- DIC disseminated intravascular coagulation
- the composition for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells are involved preferably, pancreatitis, surgical invasion, or disseminated intravascular coagulation (DIC).
- a method for enhancing preservative effectiveness of the liquid composition containing the compound of formula (1) or a salt thereof allowing the compound of formula (1) or a salt thereof and benzyl alcohol to coexist in a liquid composition and adjusting pH of the liquid composition to be 8 or more.
- the preservative effectiveness used herein is preferably preservative effectiveness against bacteria and/or fungi.
- One or more substances selected from compound 1, D-mannitol, tromethamine and benzyl alcohol were put in a 20 mL screw-cap bottle and weighed.
- Water for injection (15 mL) was poured in the bottle and mixed/dissolved by a magnetic stirrer. Thereafter, 0.1 M HCl or 0.1 M NaOH was added to adjust pH to the corresponding value shown in Table 1.
- the resultant solution was transferred to a 20 mL measuring flask and water for injection was added up to 20 mL. Thereafter, the solution was homogenized and passed through a sterile filter. In this manner, liquid compositions of the experimental plots shown in Table 1 were obtained.
- E. coli Escherichia coli
- Luria Bertani medium viable count 4.08 ⁇ 10 7 per E. coli stock solution (1 mL)
- E. coli stock solution 5 ⁇ L was inoculated/mixed in the liquid composition (500 ⁇ L) prepared in the step (a) and stored at 20 to 25° C. under dark conditions. Twenty four hours after inoculation, the number of living cells (viable count) was determined. Note that, as the viable count at 0 hours after bacterial inoculation, the viable count immediately after the E. coli stock solution was inoculated/mixed in saline, was employed.
- One or more substances selected from compound 1, D-mannitol, tromethamine and benzyl alcohol were put in a 20 mL screw-cap bottle and weighed.
- Water for injection (15 mL) was poured in the bottle and mixed/dissolved by a magnetic stirrer. Thereafter, 0.1 M HCl or 0.1 M NaOH was added to adjust pH to the corresponding value shown in Table 2.
- the resultant solution was transferred to a 20 mL measuring flask and water for injection was added up to 20 mL. Thereafter, the solution was homogenized and passed through a sterile filter. In this manner, liquid compositions of the experimental plots shown in Table 2 were obtained.
- E. coli Escherichia coli
- E. coli stock solution 5 ⁇ L was inoculated/mixed in the liquid composition (500 ⁇ L) prepared in the step (a) and stored at 20 to 25° C. under dark conditions. Twenty four hours after inoculation, the number of living cells (viable count) was determined.
- the viable count at 0 hours after bacterial inoculation was determined immediately after the E. coli stock solution was inoculated/mixed in saline. Note that, as the viable count at 0 hours after bacterial inoculation, the viable count immediately after the E. coli stock solution was inoculated/mixed in saline, was employed.
- each of the vials was punctured by a syringe with a 20-gauge needle to take out about 0.05 mL of a drug solution.
- the syringe was replaced with a new one every puncture, puncture was repeated twice.
- the vials were stored at room temperature. On day 2 and day 3, the vials were taken out and punctured once by a syringe with a 20-gauge needle to take out about 0.05 mL of the drug solution. Thereafter the vials were stored at room temperature for a predetermined period of time.
- the pH measurement was carried out in accordance with the glass electrode method.
- the antibacterial evaluation was carried out in accordance with the preservative effectiveness test specified in USP43-NF38-S2 General Chapter ⁇ 51> and Ph.Eur.10.4 General Chapter 5.1.3.
- the test microbes used in this Experimental Example were bacteria, which were Staphylococcus aureus ( S. aureus ), Pseudomonas aeruginosa ( P. aeruginosa ) and Escherichia coli ( E. coli ); and fungi, which were Candida albicans ( C. albicans ) and Aspergillus brasiliensis ( A. brasiliensis ).
- test microbes were inoculated to/mixed with the liquid compositions prepared and stored in the step (b) and incubated at 20 to 25° C. At 0 hours, 6 hours, 24 hours, Day 7, Day 14 and Day 28 after inoculation, the number of colony-forming units (CFU/mL) was counted. Note that, the number of microbes to be inoculated was controlled such that the number of colony-forming units (CFU/mL) after inoculation in a suspension became 1 ⁇ 10 5 to 1 ⁇ 10 6 . Evaluation was made based on the USP acceptance criteria for injections and other parenteral agents and Ph. Eur. acceptance criteria for parenteral preparations shown in Tables below.
- the pH of a liquid composition immediately after reconstitution was 8.7 and the pH thereof after storage for 8 days was 8.7.
- each of the vials was punctured by a syringe with a 20-gauge needle to take out about 0.05 mL of a drug solution.
- the syringe was replaced with a new one every puncture, puncture was repeated twice.
- the vials were stored in a refrigerator (2 to 8° C.). The vials were taken out from the refrigerator once a day from Day 2 to Day 13 and punctured by a syringe with a 20-gauge needle to take out about 0.05 mL of a drug solution. Thereafter, the vials were stored in the refrigerator for a predetermined period.
- test microbes used in this Experimental Example were bacteria, which were Staphylococcus aureus ( S. aureus ), Pseudomonas aeruginosa ( P. aeruginosa ) and Escherichia coli ( E. coli ); and fungi, which were Candida albicans ( C.
- test microbes were inoculated/mixed to the liquid compositions prepared and stored in the step (b) and incubated at 20 to 25° C. At 0 hours, 6 hours, 24 hours, Day 7, Day 14 and Day 28 after inoculation, the number of colony-forming units (CFU/mL) was counted. Note that, the number of microbial cells to be inoculated was controlled such that the number pf colony-forming units (CFU/mL) after inoculation in a suspension became 1 ⁇ 10 5 to 1 ⁇ 10 6 . Evaluation was made based on the same criteria as in Experimental Example 3.
- the pH of a liquid composition immediately after reconstitution was 8.7 and the pH thereof after storage for 29 days was 8.7.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
An object of the present invention is to enhance preservative effectiveness of a liquid composition containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof by using a liquid composition containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof, benzyl alcohol and water and having pH of 8 or more.
Description
- This patent application claims the priority of Japanese Patent Application No. 2020-164034 filed Sep. 29, 2020, the whole contents of which are incorporated herein by reference.
- The present invention relates to a liquid composition containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide exhibiting excellent preservative effectiveness or a salt thereof.
- N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof is known to have phospholipase A2 inhibitory action and be useful as an active ingredient of an anti-inflammatory agent or an anti-pancreatitis agent (Patent Document 1).
- Therapeutic agents or prophylactic agents for digestive disorders, liver diseases, pulmonary insufficiency or shock lung, containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof as an active ingredient, are also known (Patent Documents 2, 3, 4 and 5).
- Further, Patent Documents 1 to 5 disclose compositions for preparations such as an injection, containing the active ingredient mentioned above and also disclose that such compositions may contain an antibacterial agent such as benzyl alcohol.
- Benzyl alcohol is an antibacterial agent widely used in injections and optimal antibacterial activity thereof is exhibited at less than pH5 and virtually no antibacterial activity is exhibited beyond pH8 (non-Patent Document 1). Conversely, N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof is virtually not dissolved in water having pH5 or less. Accordingly, contrary to the disclosures of Patent Documents 1 to 5, benzyl alcohol is conceivably not appropriate as an antibacterial agent for a composition containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof.
- In the meantime, from the viewpoint of convenience for users, it has been desired to use N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof in the form of a composition such as an injection, in particular, a composition filled in a multiple-use vial, for a long period of time. Accordingly, it has been desired to develop technical means for enhancing preservative effectiveness of a liquid composition containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof.
- Patent Document 1: Japanese Patent Laid-Open No. H06-263735
- Patent Document 2: International Publication No. WO2001/056568
- Patent Document 3: International Publication No. WO2001/056569
- Patent Document 4: International Publication No. WO2001/056570
- Patent Document 5: International Publication No. WO2010/137484
- Non-Patent Document 1: Handbook of Pharmaceutical Excipients, eighth edition (2017), p.105
- In studies for the invention, the present inventors have found that, when N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof and benzyl alcohol are present together, benzyl alcohol unexpectedly exhibits antibacterial activity even at pH at which benzyl alcohol does not exhibit antibacterial activity, and enhances preservative effectiveness of a liquid composition containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof.
- Note that, N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide (Fuzapladib) is a compound represented by the structural formula of the following formula (1) and hereinafter will be sometimes simply referred to as the compound of formula (1).
-
- Accordingly, an object of the present invention is to provide a liquid composition containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof and having an enhanced preservative effectiveness.
- The following inventions are included in the present invention.
-
- [1] A composition containing:
- a compound represented by formula (1) or a salt thereof:
-
-
- benzyl alcohol; and
- water, wherein
- the composition has pH of 8 or more.
- [2] The composition according to [1], further containing a saccharide and, if desired, a pH adjuster.
- [3] The composition according to [2], wherein the saccharide is at least one selected from the group consisting of a monosaccharide, a disaccharide, a polysaccharide and a sugar alcohol.
- [4] The composition according to [2], wherein the pH adjuster is a buffer.
- [5] The composition according to any one of [1] to [4], wherein a content of benzyl alcohol in the liquid composition is 0.9 to 3 w/v %.
- [6] The composition according to any one of [1] to [5], wherein a content of the compound of formula (1) or a salt thereof in the liquid composition is 0.01 to 1 w/v %.
- [7] The composition according to any one of [1] to [6], for multiple administration.
- [8] A kit for producing the composition according to any one of [1] to [7], containing:
- a first composition containing the compound of formula (1) or a salt thereof; and
- a second composition containing benzyl alcohol and water.
- [9] The kit according to [8], wherein the first composition contains a saccharide and, if desired, a pH adjuster.
- [10] The kit according to [8] or [9], wherein a content of benzyl alcohol in the second composition is 0.9 to 3 w/v % based on the second composition.
- [11] The kit according to any one of [8] to [10], wherein the first composition is filled in a vial.
- [12] The kit according to [11], wherein the vial is a single-use vial or a multiple-use vial.
- [13] The kit according to [11], wherein the vial is a multiple-use vial.
- [14] A method for producing the composition according to any one of [1] to [7], including mixing
- a first composition containing the compound of formula (1) or a salt thereof, and
- a second composition containing benzyl alcohol and water.
- [15] A method for enhancing preservative effectiveness of a liquid composition containing the compound of formula (1) or a salt thereof, including allowing the compound of formula (1) or a salt thereof and benzyl alcohol to be present together in a liquid composition and adjusting pH of the liquid composition to be 8 or more.
- According to the present invention, preservative effectiveness in a liquid composition containing the compound of formula (1) or a salt thereof can be effectively enhanced. Accordingly, the composition of the present invention is advantageous since it is used as a composition for multiple administration, for example, a composition filled in a multiple-use vial.
- The liquid composition of the present invention is characterized by containing N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof and water together with benzyl alcohol, and having pH of 8 or more.
- N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide of the present invention is represented by the structural formula (1).
- A salt of the compound of the formula (1) may be any salt can be used as long as it is a pharmaceutically acceptable salt. Examples of the salt include alkali metal salts such as a potassium salt and a sodium salt; alkaline earth metal salts such as a calcium salt; and organic amine salts such as a triethanolamine salt and a tris (hydroxymethyl)aminomethane salt. A salt of the compound of formula (1) may be any one of these salts having crystal water, more specifically, a hydrate thereof.
- The compound of formula (1) or a salt thereof can be produced, for example, by a method disclosed in Japanese Patent Laid-Open No. H06-263735.
- According to a preferred embodiment of the present invention, the content of the compound of formula (1) or a salt thereof in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention. The content thereof can be, for example, 0.001 to 15 w/v (mass/volume) % based on the composition, preferably 0.005 to 10 w/v %, more preferably 0.01 to 5 w/v %, further preferably 0.01 to 1 w/v %, and further preferably 0.1 to 1 w/v %. The content of the compound of formula (1) or a salt thereof in the composition of the present invention can be measured by HPLC method, for example, in accordance with the method disclosed in Example 1 of International Publication No. WO2019/167979.
- In the present invention, benzyl alcohol can be used for providing preservative effectiveness.
- According to a preferred embodiment of the present invention, the content of benzyl alcohol in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention. The lower limit of the content of benzyl alcohol is, for example, 0.8 w/v % or more, preferably 0.9 w/v % or more, and more preferably 1.2 w/v % or more. Whereas, the upper limit of the content of benzyl alcohol is, for example, 5 w/v % or less, preferably 4 w/v % or less, more preferably 3 w/v % or less, and further preferably 2 w/v % or less. Accordingly, the content is, for example, 0.9 to 5 w/v % based on the composition, preferably 0.9 to 4 w/v %, more preferably 0.9 to 3 w/v %, and further preferably 1.2 to 2 w/v %. The content of benzyl alcohol in the composition of the present invention can be measured, for example, by HPLC (method) but other methods routinely used in the technical field can be used for measurement.
- According to an embodiment of the present invention, in the composition of the present invention, the mass ratio of the compound of formula (1) or a salt thereof to benzyl alcohol [mass ratio of the compound of formula (1) or a salt thereof:benzyl alcohol] can be, for example, 1:1.9 to 1:20, preferably 1:2.1 to 1:20, more preferably 1:2.2 to 1:10, and further preferably 1:3 to 1:5.
- Water to be used in the present invention is not particularly limited, for example, water that is used as a pharmaceutical or food and will be used in the future are included. Examples of water include purified water, ion-exchanged water, distilled water, hyperfiltration water, ultrapure water (for example, milli-Q water), water for injection and saline. Preferably, water for injection is used.
- According to an embodiment of the present invention, the composition may further contain a saccharide. Examples of the saccharide include, but are not particularly limited to, saccharides that are used as a pharmaceutical and food and will be used in the future.
- The saccharide of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention. Examples of the saccharide include a monosaccharide, a disaccharide, a polysaccharide, a sugar alcohol, and a combination of these. Preferably a monosaccharide, a disaccharide or a sugar alcohol, and more preferably a sugar alcohol is used.
- Examples of the monosaccharide include glucose, galactose, mannose, fructose, psicose, allose, sorbose, arabinose, galactosamine, glucosamine, xylose, thioglucose, deoxyribose, fucose, and a combination of these. Preferably glucose is used.
- Examples of the disaccharide include lactose, sucrose, maltose, isomaltose, nigerose, kojibiose, trehalose, gentiobiose, cellobiose, sophorose, nigerose, palatinose, melibiose, laminaribiose, and a combination of these. Preferably lactose is used.
- Examples of the polysaccharide include dextrin, glycogen, starch, processed starch, and a combination of these. Preferably dextrin or starch is used.
- Examples of the sugar alcohol include mannitol, sorbitol, inositol, xylitol, magnesium gluconate, maltitol, meglumine, and a combination of these. Preferably mannitol, and more preferably D-mannitol is used.
- According to another embodiment of the present invention, as the saccharide of the present invention, a water-soluble saccharide is preferable. The term “water solubility” of a saccharide that can be used in the present invention refers to a property belonging to “extremely soluble”, “easy to dissolve”, “slightly easy to dissolve” or “slightly difficult to dissolve”, which is defined in the general rule of the 17th revised Japanese Pharmacopoeia. The solubility of a saccharide of the present invention to, for example, water, is about 10 mg/mL or more at normal temperature for handling, for example, room temperature of about 20° C., preferably about 33 mg/mL or more, and more preferably 100 mg/mL or more.
- According to a preferred embodiment of the present invention, the content of a saccharide in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention but the content is, for example, 0.01 to 20 w/v % based on the composition, preferably 0.1 to 10 w/v %, and more preferably 1 to 3 w/v %.
- According to an embodiment of the present invention, the composition may further contain a pH adjuster. The pH adjuster is not particularly limited. Examples of the pH adjuster includes pH adjusters that are used as a pharmaceutical or food and will be used in the future.
- As the pH adjuster herein, a compound suitable for adjusting pH of a liquid composition to be 8 or more, for example, a value later described (for example, pH8 to 11) is used. The pH adjuster may contain a buffer. The buffer herein may be a buffer substance or buffer solution which adjusts pH, which has been changed with an acid or a base, to be a desired pH. Accordingly, the pH adjuster to be contained in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention. Examples of the pH adjuster include an acid, a base and a buffer.
- Examples of the acid include organic acids or inorganic acids. Specific acid include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, maleic acid, acetic acid, citric acid, tartaric acid, propionic acid, succinic acid, oxalic acid, lactic acid, malic acid, glutamic acid, pamoic acid, and a combination of these. Preferably, hydrochloric acid, phosphoric acid, acetic acid or citric acid may be used.
- Examples of the base include organic bases or inorganic bases. Specific base include sodium hydroxide, potassium hydroxide, ammonia, tromethamine (tris), and a combination of these. Preferably, sodium hydroxide or tromethamine (tris) may be used.
- The buffer is not particularly limited as long as it does not interfere with the effect of the present invention. Examples of the buffer include organic acid salts such as an acetate, a lactate, a tartrate, a citrate, a succinate, histidine hydrochloride and a phosphate (for example, potassium phosphate, sodium phosphate); aqueous buffers commonly known in the field of solution preparations such as a citrate buffer (for example, sodium citrate buffer), a tris buffer (for example, tris-HCl buffer), a histidine buffer, an imidazole buffer, a carbonate buffer, a triethanolamine buffer; and a combination of these.
- According to a preferred embodiment of the present invention, the concentration of an acid or a base in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention. The concentration thereof is for example, 0.001 to 2 w/v %, preferably 0.01 to 1.5 w/v %, and more preferably 0.1 to 1 w/v %.
- According to a preferred embodiment of the present invention, the concentration of a buffer in the composition of the present invention is not particularly limited as long as it does not interfere with the effect of the present invention. The concentration thereof is, for example, 1 to 500 mM, preferably 5 to 200 mM, and more preferably 10 to 100 mM.
- According to an embodiment of the present invention, the composition of the present invention may contain, optionally, a pharmaceutically acceptable additive. Examples of the pharmaceutically acceptable additive include, but are not particularly limited to, an aqueous medium, a solvent, a base, a solubilizing agent, a tonicity agent, a stabilizer, an adjuster, a chelating agent, an excipient, a thickener, a coloring agent, an antioxidant, a dispersant, an emulsifier and a solubilizer. An additive can be blended within the range in which the effect of the present invention is not impaired.
- According to an embodiment of the present invention, the dosage form of the composition of the present invention is a liquid. The composition of the present invention contains the compound of formula (1) or a salt thereof, benzyl alcohol and water in combination. The dosage form of the composition is not particularly limited as long as it keeps a characteristics of the combination. The composition can be provided as a dosage form such as an injection, a drip, a syrup or an enema. The dosage form is preferably an injection or a drip. Examples of the injection include, products prepared by filling vials or syringes with the composition of the present invention. Examples of the vial include a single-use vial or a multiple-use vial. Preferably, a multiple-use vial is used. The term “multiple” as used herein, is, for example, 2 to 20 times, and preferably, 3 to 18 times. Note that, if a multiple-use vial is used, it is preferable to maintain preservative effectiveness of the composition of the present invention even after the vial is punctured.
- According to an embodiment of the present invention, the composition of the present invention may be a composition for single administration or multiple administration, preferably multiple administration. Examples of the composition include a composition filled in a vial, preferably a composition filled in a multiple-use vial. The term “multiple” is as defined above.
- The pH of the composition of the present invention is 8 or more. From the viewpoint of improving solubility of the compound of formula (1) or a salt thereof, the pH is preferably 8 to 11 and more preferably 8 to 10. The timing of measuring pH of the composition of the present invention is not particularly limited and may be during the time of production, storage or use of the composition. The pH of the composition can be measured by a commercially available pH meter (for example, LAQUA F-74, manufactured by HORIBA Ltd.).
- According to an embodiment of the present invention, the composition of the present invention can be produced by mixing the compound of formula (1) or a salt thereof, water and benzyl alcohol, optionally, another solvent in accordance with a method commonly known in the technical field. Since the composition of the present invention may further contain a saccharide and, optionally, a pH adjuster, the composition of the present invention can be produced by mixing the compound of formula (1) or a salt thereof, water, benzyl alcohol, a saccharide and, optionally, a pH adjuster and/or another solvent in accordance with a method commonly known in the technical field. For example, the composition of the present invention is produced by mixing/dissolving the compound of formula (1) or a salt thereof, water and benzyl alcohol and, optionally, another solvent in accordance with a method commonly known in the technical field. More specifically, the composition of the present invention is produced, for example, by a method (A) in which the compound of formula (1) or a salt thereof, benzyl alcohol, a saccharide and a pH adjuster are mixed, and then, water is added; a method (B) in which water, benzyl alcohol, a saccharide and a pH adjuster are mixed, and then, the compound of formula (1) or a salt thereof is added; or a method (C) in which water, benzyl alcohol and the compound of formula (1) or a salt thereof are mixed, and then, a saccharide and a pH adjuster are added. In producing the composition of the present invention, the mixture may be subjected to homogenization and sterilization processes as long as the effect of the present invention is not impaired.
- The another solvent to be used for producing the composition of the present invention, is not particularly limited and a solvent that is used as a pharmaceutical or food and will be used in the future may be included. Examples of the another solvent include alcohols (for example, methanol, ethanol, propanol, propylene glycol), organic acids (for example, acetic acid, propionic acid), polyethylene glycol, and a mixed solvent of these.
- According to an embodiment of the present invention, it is possible to effectively enhance the preservative effectiveness of the composition of the present invention which is the liquid composition containing the compound of formula (1) of the present invention or a salt thereof. It is preferable that the preservative effectiveness complies with at least one of the standards defined in USP (for example, USP43-NF38-S2), European Pharmacopoeia (for example, Ph.Eur.10.4) and Japanese Pharmacopoeia (for example, Japanese Pharmacopoeia 17th edition, Japanese Pharmacopoeia 18th edition). Specifically, it is determined that the preservative effectiveness against, e.g., bacteria, is present if the viable count of bacterial cells decreases from 105 to 106 per the liquid composition of the present invention (1 ml or 1 g) to, for example, 102 to 103 or less, after 24 hours, preferably 101 to 102 or less, and more preferably 101 or less. It is determined that the preservative effectiveness against, e.g., fungi is present if the viable count of fungus cells per the liquid composition of the present invention (1 ml or 1 g) decreases from 105 to 106 to, for example, 103 to 104 or less after 7 days, preferably 102 to 103 or less, and more preferably 101 or less. A test for preservative effectiveness can be carried out in accordance with the preservative effectiveness test specified in USP43-NF38-S2 General Chapter<51>or Ph.Eur.10.4 General Chapter 5.1.3, in similar conditions disclosed, for example, in Experimental Examples 1, 3 and 4.
- According to an embodiment of the present invention, the subject against which the above preservative effectiveness is shown is not particularly limited, but include, for example, bacteria and/or fungi. Examples of the bacteria include Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Examples of the fungi include Candida albicans and Aspergillus brasiliensis.
- According to an embodiment of the present invention, the composition of the present invention containing the compound of formula (1) or a salt thereof and benzyl alcohol in combination can be used continuously or discontinuously for a long period of time by enhancing preservative effectiveness thereof. Specifically, the composition of the present invention can be used, for example, one day or more, preferably 7 days or more, more preferably 14 days or more, further preferably 21 days or more, and further preferably 28 days or more. The upper limit is not particularly limited but preferably 40 days or less.
- According to another embodiment of the present invention, there is provided a kit for producing the composition of the present invention disclosed above consisting of a first composition containing the compound of formula (1) or a salt thereof and a second composition containing benzyl alcohol and water.
- According to a preferred embodiment of the present invention, the first composition contains a saccharide and, optionally, a pH adjuster. The first composition may have, optionally, a pharmaceutically acceptable additive. The saccharides, pH adjuster and pharmaceutically acceptable additive herein are the same as defined above. The first composition is preferably lyophilized.
- According to a further preferred embodiment of the present invention, the first composition is filled in a vial. Examples of the vial include, a single-use vial and a multiple-use vial. Preferably, a multiple-use vial is used. The “multiple” refers to, for example, 2 to 20 times, and preferably, 3 to 18 times. Note that, if a multiple-use vial is used, preservative effectiveness of the composition of the present invention is preferably maintained even after the vial is punctured.
- According to another preferred embodiment of the present invention, the content of benzyl alcohol in the second composition is, for example, 0.9 to 5 w/v % based on the whole second composition or the whole composition of the present invention, preferably 0.9 to 4 w/v %, more preferably 0.9 to 3 w/v %, and further preferably 1.2 to 2 w/v %.
- According to another embodiment of the present invention, there is provided a method for producing the composition of the present invention, including mixing a first composition containing the compound of formula (1) or a salt thereof and a second composition containing benzyl alcohol and water. As the method, more specifically, if a first composition is filled in a vial, e.g., a method including adding a second composition to the vial to mix the first composition and the second composition is mentioned. The first composition herein is preferably lyophilized. Accordingly, the production method may be a method of reconstituting a first composition containing the compound of formula (1) or a salt thereof with benzyl alcohol and water contained in a second composition.
- According to an embodiment of the present invention, a first composition may be produced by a method of mixing/dissolving the compound of formula (1) or a salt thereof and a solvent in accordance with a method commonly known in the technical field. As described above, the first composition is preferably lyophilized. Since the first composition may contain a saccharide and, optionally, a pH adjuster, the first composition may be produced by mixing/dissolving the compound of formula (1) or a salt thereof, a saccharide, optionally, a pH adjuster and a solvent (for example, water and/or another solvent) in accordance with a method commonly known in the technical field. For example, the first composition can be produced by mixing/dissolving the compound of formula (1) or a salt thereof, a saccharide and a pH adjuster in water and/or another solvent in accordance with a method commonly known in the technical field. More specifically, the first composition of the present invention is produced, for example, by a method (A) in which the compound of formula (1) or a salt thereof, a saccharide and a pH adjuster are mixed, and then, water is added, a method (B) in which water, a saccharide and a pH adjuster are mixed, and then, the compound of formula (1) or a salt thereof is added, or a method (C) in which water and the compound of formula (1) or a salt thereof are mixed, and then a saccharide and a pH adjuster are added. Thereafter, if necessary, the solution obtained by any one of the aforementioned methods can be lyophilized. In producing the first composition, the first composition may be subjected to homogenization and sterilization processes as long as the effect of the present invention is not impaired.
- Another solvent to be used for production of the first composition is the same as defined as another solvent to be used for producing the composition of the present invention.
- According to another embodiment of the present invention, the second composition can be produced by mixing benzyl alcohol and water in accordance with a method commonly known in the technical field. In producing the second composition, the second composition may be subjected to homogenization and sterilization processes as long as the effect of the present invention is not impaired.
- According to an embodiment of the present invention, the composition of the present invention or first composition can be widely applied to diseases, disease conditions or symptoms in which inflammatory cells (for example, granulocytes (neutrophil, eosinophil, basophil), lymphocytes (for example, T lymphocytes, NK cells), monocytes, macrophages, plasma cells, mast cells, platelets) are involved. Examples of the diseases, disease conditions or symptoms include pancreatitis, surgical invasion, disseminated intravascular coagulation (DIC), neoplastic disease, pyometra, heatstroke, immune-mediated hemolytic anemia (IMHA), sepsis, angiosarcoma, gastric volvulus, ischemia reperfusion injury, purpura, liver failure, hepatitis, pneumonia, systemic inflammatory response syndrome (SIRS), external wounds, osteoarthritis, cystitis, intervertebral disc disease, atopic/allergy, dermatitis, immune-mediated disease, otitis, inflammatory bowel disease, chronic pain, colitis, chronic obstructive pulmonary disease (COPD), cholecystitis, cholangitis). Advantageously, the composition of the present invention or first composition can provide a therapeutic and preventive effect on, e.g., pancreatitis, surgical invasion and disseminated intravascular coagulation (DIC). Thus, according to another embodiment of the present invention, the composition of the present invention or first composition is provided as a composition for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells are involved, preferably, pancreatitis, surgical invasion or disseminated intravascular coagulation (DIC). The composition of the present invention or first composition can be used as a pharmaceutical product or quasi-drug for humans or animals. The composition of the present invention or first composition may be appropriately used, if necessary, in combination with another pharmaceutical product or quasi-drug commonly used in this technical field. Note that, when the first composition is applied, it is preferably used together with water and benzyl alcohol.
- According to an embodiment of the present invention, the subject to which the composition of the present invention is to be applied is, for example, an animal, preferably, a non-human animal such as a mammal, a bird, a reptile, an amphibian and fish, and more preferably, a mouse, a rat, a rabbit, a dog, a cat, a pig, a cow and a horse. The animal may be a farm animal, a pet, a human-reared animal, a wild animal and a racing animal. The subject may be a healthy person (healthy animal) or a patient (sick animal). If the composition of the present invention is composition for multiple administration, for example, if the composition of the present invention is filled in a multiple-use vial, the subject to which the composition is administered a plurality of times may be the same individual or different individuals (i.e., a plurality of individuals).
- According to another embodiment of the present invention, there is provided a method for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells of a subject are involved, preferably, pancreatitis, surgical invasion or disseminated intravascular coagulation (DIC), including administering the composition of the present invention to the subject. According to a further another embodiment of the present invention, the method for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells of a subject are involved is, if the subject is healthy, defined as a non-therapeutic method excluding a medical practice. The method for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells of a subject are involved, can be carried out in accordance with the content disclosed in the specification with respect to the composition of the present invention.
- The effective amount of the compound of formula (1) of the present invention or a salt thereof and frequency of administration of the composition of the present invention are not particularly limited and appropriately determined by those skilled in the art depending on the type and purity of the compound of formula (1) or a salt thereof, the dosage form of the composition, the type, nature, sex, age and symptom of the subject. For example, the effective amount of the compound of formula (1) or a salt thereof is 0.01 to 1000 mg/body weight (kg) and preferably 0.05 to 500 mg/body weight (kg). The frequency of administration per the same individual is, for example, 1 to 5 times per day, preferably 1 to 3 times per day, and more preferably once to twice per day. The period for administration per the same individual is, for example, 1 to 7 days, preferably 1 to 5 days, and more preferably 1 to 3 days.
- According to another embodiment of the present invention, there is provided use of the compound of formula (1) or a salt thereof, benzyl alcohol and water in combination for producing a liquid composition having pH of 8 or more. According to another preferred embodiment of the present invention, the above composition is used for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells are involved, preferably, pancreatitis, surgical invasion, or disseminated intravascular coagulation (DIC).
- According to another embodiment of the present invention, there is provided use of the compound of formula (1) or a salt thereof and benzyl alcohol in combination for enhancing preservative effectiveness of a liquid composition having pH of 8 or more. According to another preferred embodiment of the present invention, there is provided use of the above components in combination for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells are involved, preferably, pancreatitis, surgical invasion or disseminated intravascular coagulation (DIC).
- According to another embodiment of the present invention, there is provided a composition of the compound of formula (1) or a salt thereof, benzyl alcohol for enhancing preservative effectiveness of a liquid composition having pH of 8 or more. According to another preferred embodiment of the present invention, there is provided the composition for treating or preventing diseases, disease conditions or symptoms in which inflammatory cells are involved, preferably, pancreatitis, surgical invasion, or disseminated intravascular coagulation (DIC).
- According to another embodiment of the present invention, there is provided a method for enhancing preservative effectiveness of the liquid composition containing the compound of formula (1) or a salt thereof, allowing the compound of formula (1) or a salt thereof and benzyl alcohol to coexist in a liquid composition and adjusting pH of the liquid composition to be 8 or more. The preservative effectiveness used herein is preferably preservative effectiveness against bacteria and/or fungi.
- The embodiments of the use, combination and composition each can be carried out in accordance with the disclosure of the composition and method of the present invention.
- Now, the present invention will be more specifically described by way of the following Experimental Examples, but the technical scope of the present invention is not limited by these examples. Unless otherwise specified, units and measuring methods disclosed herein follow the JIS standard.
- Substances used in Experimental Examples are as follows.
-
- Compound 1: N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide, monosodium salt, monohydrate (Fuzapladib sodium hydrate)
- D-mannitol: manufactured by Nacalai Tesque Inc. (Experimental Examples 1, 2), manufactured by Roquette Freres (Experimental Examples 3, 4)
- Tromethamine: manufactured by Nacalai Tesque Inc. (Experimental Examples 1, 2), manufactured by Biospectra, Inc. (Experimental Examples 3, 4)
- Benzyl alcohol: manufactured by Spectrum Chemical Manufacturing Crop. (Experimental Examples 1, 2), manufactured by Lanxess Deutschland GmbH (Experimental Examples 3, 4)
- Apparatuses used in Experimental Examples are as follows.
-
- Magnetic stirrer: Pasolina Mini Stirrer CT-1AT, manufactured by AS ONE Corporation (Experimental Examples 1, 2)
- High Shear Mixer: BX-60, manufactured by Silverson (Experimental Examples 3, 4)
- pH meter: LAQUA F-74, manufactured by HORIBA Ltd.
- Sterile filter: DISMIC-25AS, manufactured by ADVANTEC (Experimental Examples 1, 2), KA2EKVP1G, manufactured by Pall Manufacturing Ltd. (Experimental Examples 3, 4)
- One or more substances selected from compound 1, D-mannitol, tromethamine and benzyl alcohol were put in a 20 mL screw-cap bottle and weighed. Water for injection (15 mL) was poured in the bottle and mixed/dissolved by a magnetic stirrer. Thereafter, 0.1 M HCl or 0.1 M NaOH was added to adjust pH to the corresponding value shown in Table 1. The resultant solution was transferred to a 20 mL measuring flask and water for injection was added up to 20 mL. Thereafter, the solution was homogenized and passed through a sterile filter. In this manner, liquid compositions of the experimental plots shown in Table 1 were obtained.
- Antibacterial evaluation was carried out with reference to preservative effectiveness test (Efficacy of Antimicrobial Preservation) of the European Pharmacopeia 9.0, as follows. A stock solution of Escherichia coli (hereinafter referred to also as E. coli) was prepared using Luria Bertani medium (viable count 4.08×107 per E. coli stock solution (1 mL)). Thereafter, E. coli stock solution (5 μL) was inoculated/mixed in the liquid composition (500 μL) prepared in the step (a) and stored at 20 to 25° C. under dark conditions. Twenty four hours after inoculation, the number of living cells (viable count) was determined. Note that, as the viable count at 0 hours after bacterial inoculation, the viable count immediately after the E. coli stock solution was inoculated/mixed in saline, was employed.
-
TABLE 1 Experimental plot 1 2 3 4 Saline Compound 1 (w/v %) 0.4 0.4 — 0.4 — D-mannitol 1.5 1.5 — — (w/v %) Tromethamine 0.6 0.6 — — (w/v %) Benzyl alcohol 0.9 — 0.9 0.9 (w/v %) pH 8.7 8.7 8.8 8.7 — Viable 0 hr. after — — — — 4.08 × 105 (cells/mL) inoculation count 24 hr. after 0 1.69 × 105 8.90 × 103 0 — inoculation - In the case (experimental plot 3) containing benzyl alcohol alone at pH8.7 to 8.8, living cells remained 24 hours after inoculation. It was found that the antibacterial efficacy (i.e., preservative effectiveness) of this case was not sufficient. However, in the cases (experimental plot 1 and 4) where benzyl alcohol and compound 1 were mixed, the vial count 24 hours after inoculation was 0. It was found that antibacterial efficacy was significantly enhanced.
- One or more substances selected from compound 1, D-mannitol, tromethamine and benzyl alcohol were put in a 20 mL screw-cap bottle and weighed. Water for injection (15 mL) was poured in the bottle and mixed/dissolved by a magnetic stirrer. Thereafter, 0.1 M HCl or 0.1 M NaOH was added to adjust pH to the corresponding value shown in Table 2. The resultant solution was transferred to a 20 mL measuring flask and water for injection was added up to 20 mL. Thereafter, the solution was homogenized and passed through a sterile filter. In this manner, liquid compositions of the experimental plots shown in Table 2 were obtained.
- Antibacterial evaluation was carried out with reference to preservative effectiveness test (Efficacy of Antimicrobial Preservation) of the European Pharmacopeia 9.0, as follows. A stock solution of Escherichia coli (hereinafter referred to also as E. coli) was prepared in the same manner as in Experimental Example 1 (viable count 9.90×107 per E. coli stock solution (1 mL)). Thereafter, E. coli stock solution (5 μL) was inoculated/mixed in the liquid composition (500 μL) prepared in the step (a) and stored at 20 to 25° C. under dark conditions. Twenty four hours after inoculation, the number of living cells (viable count) was determined. Note that, the viable count at 0 hours after bacterial inoculation was determined immediately after the E. coli stock solution was inoculated/mixed in saline. Note that, as the viable count at 0 hours after bacterial inoculation, the viable count immediately after the E. coli stock solution was inoculated/mixed in saline, was employed.
-
TABLE 2 Experimental plot 5 6 7 8 9 10 Saline Compound 1 — — 0.4 0.4 — 0.4 — (w/v %) D-mannitol — — — — — 1.5 (w/v %) Tromethamine — — — — — 0.6 (w/v %) Benzyl alcohol 0.9 0.9 — 0.9 0.8 0.8 (w/v %) pH 4.9 8.7 8.7 8.7 8.7 8.7 — Viable 0 hr. — — — — — — 9.90 × 105 count after (cells/ inoculation mL) 24 hr. 0 6.70 × 104 8.00 × 105 0 3.64 × 105 5.00 × 102 — after inoculation - In the cases containing benzyl alcohol alone, antibacterial efficacy was shown at pH4.9 (experimental plot 5), but virtually no antibacterial efficacy was shown at pH8.7 (experimental plot 6). Also, in the case (experimental plot 7) containing compound 1 alone at pH8.7, virtually no antibacterial efficacy was shown. However, in the case containing benzyl alcohol and compound 1 in combination (experimental plot 8), viable count 24 hours after inoculation pH8.7 was 0. It was found that antibacterial efficacy was significantly enhanced.
- Compound 1 (160 g), D-mannitol (600 g), tromethamine (240 g) and water (17 kg) were mixed. After pH of the mixture was adjusted to be pH8.7 with 1 M hydrochloric acid, water was added to the mixture up to 20 L. The resultant mixture was filtered/sterilized by a 0.2 μm filter. A vial is load with 1.75 mL of the filtrate, capped half with a rubber stopper and lyophilized. After lyophilization, the vial was fully capped with the rubber stopper and wrapped with aluminum seal to obtain a lyophilized preparation.
- Into the vial obtained in the step (a), water for injection (3.5 mL) containing 1.8 w/v % benzyl alcohol was injected by a syringe with a 20-gauge needle. In this manner, the lyophilized preparation was reconstituted to obtain a liquid composition.
- Each of the vials was punctured by a syringe with a 20-gauge needle to take out about 0.05 mL of a drug solution. The syringe was replaced with a new one every puncture, puncture was repeated twice. The vials were stored at room temperature. On day 2 and day 3, the vials were taken out and punctured once by a syringe with a 20-gauge needle to take out about 0.05 mL of the drug solution. Thereafter the vials were stored at room temperature for a predetermined period of time.
- Immediately after reconstitution, pH was measured. On day 8, pH measurement and antibacterial evaluation were carried out.
- The pH measurement was carried out in accordance with the glass electrode method.
- The antibacterial evaluation was carried out in accordance with the preservative effectiveness test specified in USP43-NF38-S2 General Chapter <51> and Ph.Eur.10.4 General Chapter 5.1.3. The test microbes used in this Experimental Example were bacteria, which were Staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and Escherichia coli (E. coli); and fungi, which were Candida albicans (C. albicans) and Aspergillus brasiliensis (A. brasiliensis). The test microbes were inoculated to/mixed with the liquid compositions prepared and stored in the step (b) and incubated at 20 to 25° C. At 0 hours, 6 hours, 24 hours, Day 7, Day 14 and Day 28 after inoculation, the number of colony-forming units (CFU/mL) was counted. Note that, the number of microbes to be inoculated was controlled such that the number of colony-forming units (CFU/mL) after inoculation in a suspension became 1×105 to 1×106. Evaluation was made based on the USP acceptance criteria for injections and other parenteral agents and Ph. Eur. acceptance criteria for parenteral preparations shown in Tables below.
-
TABLE 3 USP acceptance criteria for injections and other parenteral agents Day 7 Day 14 Day 28 Bacteria Logarithmic Logarithmic No increase from decrement of 1.0 decrement of 3.0 Day 14 count from initial count from initial count Fungi No increase from No increase from No increase from initial count initial count initial count -
TABLE 4 Ph. Eur. acceptance criteria for parenteral preparations Logarithmic decrement Criterium 6 hours 24 hours Day 7 Day 14 Day 28 Bacteria A 2 3 NR B 1 3 NI Fungi A 2 NI B 1 NI *NI: no increase in number of viable microbe cells compared to previous measurement. *NR: no recovery of specified microbe. -
-
- 1. pH of liquid composition
- The pH of a liquid composition immediately after reconstitution was 8.7 and the pH thereof after storage for 8 days was 8.7.
-
- 2. Antibacterial activity of liquid composition after storage for 8 days.
- The results are shown in the Table below. The liquid composition of this example complied with the USP acceptance criteria for injections and other parenteral agents and Ph. Eur. acceptance criteria for parenteral preparations.
-
TABLE 5 Number of inoculated Logarithmic decrement cells 0 6 24 Day Day Day Criterium Test microbe (CFU/mL) hours hours hours 7 14 28 USP Ph. Eur. S.aureus 3.3 × 105 1.4 4.2 >4.5 >4.5 >4.5 >4.5 Pass A P.aeruginosa 1.5 × 105 >4.2 >4.2 >4.2 >4.2 >4.2 >4.2 Pass A E.coli 9.6 × 105 >5.0 >5.0 >5.0 >5.0 >5.0 >5.0 Pass *NC C.albicans 4.2 × 105 1.6 3.0 >4.6 >4.6 >4.6 >4.6 Pass A A.brasiliensis 2.3 × 105 0.0 0.1 2.5 >4.4 >4.4 >4.4 Pass A *NC: According to Ph.Eur. 5.1.3, E. coli is not identified as challenge microbe. - Compound 1 (160 g), D-mannitol (600 g), tromethamine (240 g) and water (17 kg) were mixed. After pH of the mixture was adjusted to be pH8.7 with 1 M hydrochloric acid, water was added to the mixture up to 20 L. The resultant mixture was filtered/sterilized by a 0.2 μm filter. A vial is loaded with 1.75 mL of the filtrate, capped half with a rubber stopper, and lyophilized. After lyophilization, the vial was fully capped with the rubber stopper and wrapped with aluminum seal to obtain a lyophilized preparation.
- Into the vial obtained in the step (a), water for injection (3.5 mL) containing 1.8 w/v % benzyl alcohol was injected by a syringe with a 20-gauge needle. In this manner, the lyophilized preparation was reconstituted to obtain a liquid composition.
- Each of the vials was punctured by a syringe with a 20-gauge needle to take out about 0.05 mL of a drug solution. The syringe was replaced with a new one every puncture, puncture was repeated twice. The vials were stored in a refrigerator (2 to 8° C.). The vials were taken out from the refrigerator once a day from Day 2 to Day 13 and punctured by a syringe with a 20-gauge needle to take out about 0.05 mL of a drug solution. Thereafter, the vials were stored in the refrigerator for a predetermined period.
- Immediately after the reconstitution, pH was measured. On day 29, the vials were taken out from the refrigerator and pH measurement and antibacterial evaluation were carried out. The pH measurement was carried out in accordance with the glass electrode method. The antibacterial evaluation was carried out in accordance with the preservative effectiveness test specified in USP43-NF38-S2 General Chapter<51> and Ph.Eur.10.4 General Chapter 5.1.3. The test microbes used in this Experimental Example were bacteria, which were Staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and Escherichia coli (E. coli); and fungi, which were Candida albicans (C. albicans) and Aspergillus brasiliensis (A. brasiliensis). The test microbes were inoculated/mixed to the liquid compositions prepared and stored in the step (b) and incubated at 20 to 25° C. At 0 hours, 6 hours, 24 hours, Day 7, Day 14 and Day 28 after inoculation, the number of colony-forming units (CFU/mL) was counted. Note that, the number of microbial cells to be inoculated was controlled such that the number pf colony-forming units (CFU/mL) after inoculation in a suspension became 1×105 to 1×106. Evaluation was made based on the same criteria as in Experimental Example 3.
-
-
- 1. pH of liquid composition
- The pH of a liquid composition immediately after reconstitution was 8.7 and the pH thereof after storage for 29 days was 8.7.
-
- 2. Antibacterial activity of liquid composition after storage for 29 days
- The results are shown in the Table below. As shown in the Table, the liquid composition of this example complied with the USP acceptance criteria for injections and other parenteral agents and Ph. Eur. acceptance criteria for parenteral preparations.
-
TABLE 6 Number of inoculated Logarithmic decrement cells 0 6 24 Day Day Day Criterium Test microbe (CFU/mL) hours hours hours 7 14 28 USP Ph.Eur. S.aureus 4.0 × 105 1.1 >4.6 >4.6 >4.6 >4.6 >4.6 Pass A P.aeruginosa 1.5 × 105 >4.2 >4.2 >4.2 >4.2 >4.2 >4.2 Pass A E.coli 9.1 × 105 >5.0 >5.0 >5.0 >5.0 >5.0 >5.0 Pass *NC C.albicans 3.9 × 105 1.0 3.0 4.6 >4.6 >4.6 >4.6 Pass A A.brasiliensis 2.4 × 105 0.0 0.2 3.2 >4.4 >4.4 >4.4 Pass A *NC: According to Ph.Eur. 5.1.3, E. coli is not identified as challenge microbe.
Claims (14)
1. A liquid composition comprising:
a compound represented by formula (1) or a salt thereof:
benzyl alcohol; and
water, wherein
the composition has pH of 8 or more.
2. The composition according to claim 1 , further comprising a saccharide and, optionally, a pH adjuster.
3. The composition according to claim 2 , wherein the saccharide is at least one selected from the group consisting of a monosaccharide, a disaccharide, a polysaccharide and a sugar alcohol.
4. The composition according to claim 2 , wherein the pH adjuster is a buffer.
5. The composition according to any one of claims 1 to 4 , wherein a content of benzyl alcohol in the liquid composition is 0.9 to 3 w/v %.
6. The composition according to any one of claims 1 to 5 , wherein a content of the compound of formula (1) or a salt thereof in the liquid composition is 0.01 to 1 w/v %.
7. The composition according to any one of claims 1 to 6 , for multiple administration.
8. A kit for producing the composition according to any one of claims 1 to 7 , comprising:
a first composition containing the compound of formula (1) or a salt thereof; and
a second composition containing benzyl alcohol and water.
9. The kit according to claim 8 , wherein the first composition contains a saccharide and, optionally, a pH adjuster.
10. The kit according to claim 8 or 9 , wherein a content of benzyl alcohol in the second composition is 0.9 to 3 w/v % based on the second composition.
11. The kit according to any one of claims 8 to 10 , wherein the first composition is filled in a vial.
12. The kit according to claim 11 , wherein the vial is a single-use vial or a multiple-use vial.
13. A method for producing the composition according to any one of claims 1 to 7 , comprising mixing
a first composition containing the compound of formula (1) or a salt thereof, and
a second composition containing benzyl alcohol and water.
14. A method for enhancing preservative effectiveness of a liquid composition comprising the compound of formula (1) or a salt thereof, comprising allowing the compound of formula (1) or a salt thereof and benzyl alcohol to be present together in a liquid composition and adjusting pH of the liquid composition to be 8 or more.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-164034 | 2020-09-29 | ||
| JP2020164034 | 2020-09-29 | ||
| PCT/JP2021/035417 WO2022071233A1 (en) | 2020-09-29 | 2021-09-27 | Liquid pharmaceutical composition demonstrating excellent preservation efficacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20230372315A1 true US20230372315A1 (en) | 2023-11-23 |
Family
ID=80949079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US18/246,775 Pending US20230372315A1 (en) | 2020-09-29 | 2021-09-27 | Liquid-State Pharmaceutical Composition Exhibiting Excellent Preservative Effectiveness |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230372315A1 (en) |
| EP (1) | EP4223295A1 (en) |
| JP (1) | JPWO2022071233A1 (en) |
| KR (1) | KR20230084205A (en) |
| CN (1) | CN116472032A (en) |
| AU (1) | AU2021354445A1 (en) |
| BR (1) | BR112023005756A2 (en) |
| CA (1) | CA3194011A1 (en) |
| CL (1) | CL2023000871A1 (en) |
| CO (1) | CO2023003536A2 (en) |
| EC (1) | ECSP23020965A (en) |
| MX (1) | MX2023003603A (en) |
| PE (1) | PE20240109A1 (en) |
| TW (1) | TW202222347A (en) |
| WO (1) | WO2022071233A1 (en) |
| ZA (1) | ZA202303906B (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69127595T2 (en) | 1990-07-10 | 1998-01-22 | Ishihara Sangyo Kaisha | Diaminotrifluoromethylpyrimidine derivatives, processes for their preparation and phospholipase A2 inhibitors containing them |
| IL150965A0 (en) * | 2000-01-31 | 2003-02-12 | Ishihara Sangyo Kaisha | Therapeutic or preventive agent for digestive system diseases containing a diaminotrifluoromethylpyridine derivative |
| AU2001228862A1 (en) | 2000-02-01 | 2001-08-14 | Ishihara Sangyo Kaisha Ltd. | Remedies or preventives for liver diseases containing diaminotrifluoromethylpyridine derivatives |
| JP4848092B2 (en) | 2000-02-01 | 2011-12-28 | 石原産業株式会社 | Therapeutic or preventive agent for lung failure containing a diaminotrifluoromethylpyridine derivative |
| JP5584518B2 (en) | 2009-05-28 | 2014-09-03 | 石原産業株式会社 | Anti-shock agent containing diaminotrifluoromethylpyridine derivative |
| DE112010003355T5 (en) * | 2009-08-21 | 2012-07-12 | Targeted Delivery Technologies Ltd. | Vesicular formulations |
| US20160193147A1 (en) * | 2013-07-31 | 2016-07-07 | Sequessome Technology Holdings Limited | Vesicles |
| CA3092616A1 (en) | 2018-03-01 | 2019-09-06 | Ishihara Sangyo Kaisha, Ltd. | Pharmaceutical composition with excellent storage stability |
-
2021
- 2021-09-27 JP JP2022553959A patent/JPWO2022071233A1/ja active Pending
- 2021-09-27 CA CA3194011A patent/CA3194011A1/en active Pending
- 2021-09-27 KR KR1020237014639A patent/KR20230084205A/en unknown
- 2021-09-27 US US18/246,775 patent/US20230372315A1/en active Pending
- 2021-09-27 BR BR112023005756A patent/BR112023005756A2/en unknown
- 2021-09-27 MX MX2023003603A patent/MX2023003603A/en unknown
- 2021-09-27 AU AU2021354445A patent/AU2021354445A1/en active Pending
- 2021-09-27 WO PCT/JP2021/035417 patent/WO2022071233A1/en active Application Filing
- 2021-09-27 CN CN202180066887.2A patent/CN116472032A/en active Pending
- 2021-09-27 EP EP21875535.3A patent/EP4223295A1/en active Pending
- 2021-09-27 PE PE2023001208A patent/PE20240109A1/en unknown
- 2021-09-29 TW TW110136251A patent/TW202222347A/en unknown
-
2023
- 2023-03-22 EC ECSENADI202320965A patent/ECSP23020965A/en unknown
- 2023-03-22 CO CONC2023/0003536A patent/CO2023003536A2/en unknown
- 2023-03-24 CL CL2023000871A patent/CL2023000871A1/en unknown
- 2023-03-28 ZA ZA2023/03906A patent/ZA202303906B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023005756A2 (en) | 2023-05-09 |
| ECSP23020965A (en) | 2023-04-28 |
| EP4223295A1 (en) | 2023-08-09 |
| KR20230084205A (en) | 2023-06-12 |
| CN116472032A (en) | 2023-07-21 |
| WO2022071233A1 (en) | 2022-04-07 |
| CA3194011A1 (en) | 2022-04-07 |
| JPWO2022071233A1 (en) | 2022-04-07 |
| AU2021354445A1 (en) | 2023-05-18 |
| CO2023003536A2 (en) | 2023-05-29 |
| ZA202303906B (en) | 2024-06-26 |
| CL2023000871A1 (en) | 2023-11-10 |
| MX2023003603A (en) | 2023-04-05 |
| PE20240109A1 (en) | 2024-01-22 |
| TW202222347A (en) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007322334B2 (en) | Method of drug delivery for bone anabolic protein | |
| KR20040085196A (en) | Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same | |
| US20140274992A1 (en) | Ceftolozane pharmaceutical compositions | |
| RU2770366C2 (en) | Daptomycin preparations | |
| JP2014507484A (en) | Stable formulation for parenteral injection of peptide drugs | |
| KR100869752B1 (en) | Pharmaceutical solutions of levosimendan | |
| JP2013537212A (en) | Caspofungin composition | |
| US20030161871A1 (en) | Solubilized riboflavin | |
| US20150216928A1 (en) | Daptomycin injectable formulation | |
| CN107106659B (en) | Parenteral glucagon formulations | |
| US20230372315A1 (en) | Liquid-State Pharmaceutical Composition Exhibiting Excellent Preservative Effectiveness | |
| KR100807650B1 (en) | FREEZE-DRIED PREPARATION OF N-[o-p-PIVALOYLOXYBENZENESULFONYLAMINOBENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME | |
| JP6120834B2 (en) | Antiparasitic compositions comprising macrocyclic lactones and levamisole, and methods of treating parasitic infections | |
| US20200330441A1 (en) | Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and methods for using same | |
| JP5322649B2 (en) | Cefquinome composition and method of use thereof | |
| US20040072909A1 (en) | Veterinary compositions for the treatment of parasitic diseases | |
| US20160339002A1 (en) | Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and method for using same | |
| US20230068866A1 (en) | Daptomycin formulation | |
| AU2016210773B2 (en) | An anti-parasitic formulation and a method for treating parasitic infestations in an animal | |
| KR20210143874A (en) | Pregabalin formulations and uses thereof | |
| AU2012201490B2 (en) | Method of drug delivery for bone anabolic protein | |
| KR20240072273A (en) | Conjugate drug preparation, preparation method and use thereof | |
| EP4364566A1 (en) | Anti-fungal composition | |
| KR20220033561A (en) | Pharmaceutical composition of premix formulation containing peramivir compound | |
| JP2013006825A (en) | Pharmaceutical composition and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
| AS | Assignment |
Owner name: ISHIHARA SANGYO KAISHA, LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHINDO, TAKESHI;REEL/FRAME:063609/0308 Effective date: 20230417 |
|
| AS | Assignment |
Owner name: ISHIHARA SANGYO KAISHA, LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHINDO, TAKESHI;REEL/FRAME:064071/0782 Effective date: 20230417 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |